MCT1 inhibitor AZD3965 has shown efficacy as an antitumor agent in different types of cancer, both in vivo and in vitro, with promising results and a Phase I clinical trial has already been completed in the UK [81]. This evidence concerns the gene SLC16A1 and cancer.